Brii Biosciences Limited (7SS) - Total Liabilities
Based on the latest financial reports, Brii Biosciences Limited (7SS) has total liabilities worth €36.20 Million EUR (≈ $42.32 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Brii Biosciences Limited equity growth rate to track the company's year-over-year net asset growth rate.
Brii Biosciences Limited - Total Liabilities Trend (2020–2025)
This chart illustrates how Brii Biosciences Limited's total liabilities have evolved over time, based on quarterly financial data.
Brii Biosciences Limited Competitors by Total Liabilities
The table below lists competitors of Brii Biosciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanoform Finland Plc
HE:NANOFH
|
Finland | €12.56 Million |
|
e-LITECOM CO. Ltd
KQ:041520
|
Korea | ₩10.24 Billion |
|
Flexible Solutions International Inc
NYSE MKT:FSI
|
USA | $19.00 Million |
|
FELIX Gold Ltd
AU:FXG
|
Australia | AU$1.22 Million |
|
Teads B.V.
NASDAQ:TEAD
|
USA | $1.15 Billion |
|
Resource Alam Indonesia Tbk
JK:KKGI
|
Indonesia | Rp33.58 Million |
|
Canterbury Park Holding Corporation
NASDAQ:CPHC
|
USA | $18.90 Million |
|
Pricer AB (publ)
ST:PRIC-B
|
Sweden | Skr1.03 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Brii Biosciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 7SS company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 60.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Brii Biosciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Brii Biosciences Limited (2020–2025)
The table below shows the annual total liabilities of Brii Biosciences Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €36.20 Million ≈ $42.32 Million |
-63.99% |
| 2024-12-31 | €100.55 Million ≈ $117.55 Million |
-20.12% |
| 2023-12-31 | €125.87 Million ≈ $147.15 Million |
-46.29% |
| 2022-12-31 | €234.35 Million ≈ $273.98 Million |
-22.00% |
| 2021-12-31 | €300.44 Million ≈ $351.25 Million |
-90.02% |
| 2020-12-31 | €3.01 Billion ≈ $3.52 Billion |
-- |
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more